Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has bolstered its commercial development expertise with the appointment of Dr John Prendergast as executive chair, effective immediately.
Based in the US, Dr Prendergast joined RCE in 2018 as non-executive director before making the switch to non-executive chair in 2019 and has now made this second transition to executive chair.
In his new role, Dr Prendergast will work alongside CEO James Graham to advance Recce’s synthetic anti-infective programs both locally and internationally.
“Veteran in biotechnology”
“We are delighted to welcome Dr Prendergast to a more active role active in the operational team,” Recce Pharmaceuticals CEO James Graham said.
“Bringing a depth of knowledge and well-recognised capability as a veteran in biotechnology and international capital markets, we greatly look forward to his continued contributions over the time ahead.”
Dr Prendergast has a background in microbiology and experience in commercialising pharmaceuticals for global markets with a particular emphasis on the US.
He currently serves as non-executive chair and co-founder of Palatin Technologies, and lead director of Nighthawk Biosciences, Inc.
“I am delighted to work alongside the expertise I’ve witnessed among the Recce team over these last four years,” Prendergast said.
“We are excited about the data from our current clinical programs and have great aspirations as we advance for our future Phase I & Phase II clinical trials as well as a suite of pre-clinical programs for a range of indications.
“Together with the support of our clinical collaborators, business partners and shareholders, we are proudly building a company with real global impact positioned to address and deliver on one of the greatest unmet medical needs currently faced by humanity.”